Effect of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Infants in China

NCT ID: NCT01373541

Last Updated: 2014-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

171 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of infant formula with high percentage of palmitic acid at the sn-2 position (InFat™) on improving fat absorption and general gastrointestinal tolerance in Chinese formula-fed term infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to assess the efficacy of infant formula with high percentage of palmitic acid at the sn-2 position (InFat™) as compared to standard vegetable oil based infant formula on general gastrointestinal tolerance and fat absorption, reducing calcium soaps formation and stool hardness in Chinese formula-fed term infants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Health Behavior Personal Satisfaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

InFat group

Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)

Group Type ACTIVE_COMPARATOR

InFat™ based infant formula

Intervention Type OTHER

high sn-2 palmitic acid oil based infant formula

Control group

Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)

Group Type ACTIVE_COMPARATOR

Standard vegetable oil based infant formula

Intervention Type OTHER

standard vegetable oil based infant formula

Referance group

Human milk breastfeeding

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

InFat™ based infant formula

high sn-2 palmitic acid oil based infant formula

Intervention Type OTHER

Standard vegetable oil based infant formula

standard vegetable oil based infant formula

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

high sn-2 palmitic acid structured triglyceride standard vegetable oil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parental/legal guardian written informed consent;
* The mother had unequivocally decided not to breast-feed (for formula fed infants) or to breastfeed (for human milk fed infants).
* Term infant of Chinese origin born at 37-42 gestation weeks
* Birth weight appropriate for gestational age (AGA), 2500-4000grams
* The infant is apparently healthy at birth and entry of study.

Exclusion Criteria

* Adverse maternal, fetal or infant medical history that can potentially affect efficacy parameters, tolerance, growth and/or development
* The infant is not a singleton newborn
Minimum Eligible Age

1 Day

Maximum Eligible Age

14 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biostime, Inc. (Guangzhou)

INDUSTRY

Sponsor Role collaborator

Enzymotec

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xu Chundix, Prof.

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rui Jin Hospital - Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Bar-Yoseph F, Lifshitz Y, Cohen T, Malard P, Xu C. SN2-Palmitate Reduces Fatty Acid Excretion in Chinese Formula-fed Infants. J Pediatr Gastroenterol Nutr. 2016 Feb;62(2):341-7. doi: 10.1097/MPG.0000000000000971.

Reference Type DERIVED
PMID: 26334255 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

InFat_003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.